Posts Tagged ‘Ricard Cervera’

Categories

Posted in:

Friday July 18th, 2014

IDIBAPS is the Spanish entity with more activities funded by the Innovative Medicines Initiative

The report named “Spanish Participation in the Innovative Medicines Initiative (IMI)” has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.

Read the rest of this entry »

Comments Closed
Wednesday February 19th, 2014

The Systemic Autoimmune Diseases research group of IDIBAPS coleads PRECISESADS, an European project to reclassify autoimmune diseases

 The Systemic Autoimmune Diseases research group of IDIBAPS lead by Dr. Ricard  Cervera coleads the clinical aspect of the European project PRECISESADS, which is  planned 5-year study in 2.000 patients with various diseases: systemic lupus  erythematosus, systemic sclerosis, Sjogren’s syndrome, antiphospholipid syndrome or  mixed connective tissue disease. These diseases currently are diagnosed based on  clinical criteria relatively nonspecific often do not allow early diagnosis and, moreover,  dealt mainly with anti-inflammatory drugs and immunosuppressants also nonspecific .  The detection of new biomarkers should facilitate speed diagnosis and help in making  therapeutic decisions.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday December 15th, 2011

Commemoració dels 25 anys de Malalties Autoimmunes a l’Hospital Clínic

Read the rest of this entry »

Comments Closed
Friday November 25th, 2011

Belimumab is the first treatment specifically developed for SLE in over 50 years

El Dr. Ricard Cervera A la presentació de BENLYSTA

GlaxoSmithKline (GSK) and Human Genome Sciences (HGS) presented BENLYSTA (belimumab). This is a treatment for adult patients with systemic lupus erythematosus (SLE) who have a high degree of disease activity and in which the disease is not controlled despite receiving therapies. This drug is a treatment specifically indicated for reducing disease activity in SLE. Dr. Ricard Cervera, head of Department of Autoimmune Diseases at IDIBAPS – Hospital Clínic of Barcelona and one of the principal investigators of this drug, has participated in the presentation.

Read the rest of this entry »

Comments Closed